Cost-effectiveness of as-needed budesonide-formoterol in adults with mild asthma: the Novel START trial
For patients with mild asthma, as-needed budesonide-formoterol 200/6 μg is cost-saving from health-system, patient and societal perspectives, while improving outcomes, dominating maintenance budesonide plus as-needed salbutamol. Compared with as-needed salbutamol, as-needed budesonide-formoterol is cost-effective from a health-system perspective and dominates from a societal perspective.
Authors
- Ilka Pelzer
- Helen Kathryn Reddel (ORCID: https://orcid.org/0000-0002-6695-6350)
- Trudy Sullivan (ORCID: https://orcid.org/0000-0001-8452-2591)
- Tim W Harrison (ORCID: https://orcid.org/0000-0002-3065-8247)
- Stefan Ebmeier (ORCID: https://orcid.org/0000-0001-7570-7172)
- Alberto Papi (ORCID: https://orcid.org/0000-0002-6924-4500)
- Michael George Baker (ORCID: https://orcid.org/0000-0002-1865-1536)
- Mark W Weatherall (ORCID: https://orcid.org/0000-0002-0051-9107)
- Richard Beasley (ORCID: https://orcid.org/0000-0003-0337-406X)
- Mark Holliday (ORCID: https://orcid.org/0000-0003-2344-6091)
- Ian Pavord (ORCID: https://orcid.org/0000-0002-4288-5973)
- Tsung-Chieh Hung
- Robert J. Hancox (ORCID: https://orcid.org/0000-0002-3922-7144)
- William Leung (ORCID: https://orcid.org/0000-0001-7363-0239)
Institutions
- University of Nottingham (GB)
- University of Auckland (NZ)
- University of Ferrara (IT)
- Woolcock Institute of Medical Research (AU)
- Waikato Hospital (NZ)
- University of Oxford (GB)
- AstraZeneca (France) (FR)
- Capital and Coast District Health Board (NZ)
- Technical University of Applied Sciences Lübeck (DE)
- Medical Research Institute of New Zealand (NZ)
- AstraZeneca (Poland) (PL)
- Sydney Local Health District (AU)
- Oxford BioMedica (United Kingdom) (GB)
- Nottingham Biomedical Research Centre (GB)
- Imperial College London (GB)
- Cardiff University (GB)
- University of Otago (NZ)
- Macquarie University (AU)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1183/23120541.00949-2025
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00